Cited by 173Ovarian function and disordersSirtuins and Resveratrol in MedicineReproductive Biology and Fertility

Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial

Banaszewska, Beata, Wrotyńska-Barczyńska, Joanna, Spaczynski, Robert Z., Pawelczyk, Leszek, Duleba, Antoni J.·2016·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Hyperandrogenism is the central feature of PCOS. Studies on isolated ovarian theca-interstitial cells suggest that resveratrol, a natural polyphenol, reduces androgen production. OBJECTIVE: This study was designed to evaluate endocrine and metabolic effects of resveratrol on PCOS. DESIGN AND SETTING: This was a randomized (1:1) double-blind, placebo-controlled trial that evaluated the effects of resveratrol over a period of 3 months in an academic hospital. PATIENTS AND OTHER PARTICIPANTS: Subjects with PCOS were identified according to the Rotterdam criteria. Thirty-four subjects were enrolled and 30 subjects completed the trial. Evaluations were performed at baseline and repeated after 3 months of treatment. INTERVENTION: Resveratrol (1,500 mg p.o.) or placebo were administered daily. MAIN OUTCOME MEASURE: Primary outcome was the change in the serum total T. RESULTS: Resveratrol treatment led to a significant decrease of total T by 23.1% (P = .01). In parallel, resveratrol induced a 22.2% decrease of dehydroepiandrosterone sulfate (P = .01), a decrease of fasting insulin level by 31.8% (P = .007) and an increase of the Insulin Sensitivity Index (Matsuda and DeFronzo) by 66.3% (P = .04). Levels of gonadotropins, the lipid profile as well as markers of inflammation and endothelial function were not significantly altered. CONCLUSIONS: Resveratrol significantly reduced ovarian and adrenal androgens. This effect may be, at least in part, related to an improvement of insulin sensitivity and a decline of insulin level.

Integrity signals

Registry

Crossref · 10.1210/jc.2016-1858

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a randomized placebo-controlled trial, treatment with 1500 mg daily of resveratrol significantly decreased testosterone and dehydroepiandrosterone sulfate excess by ~23% in PCOS women over 3 months.

    “In a randomized placebo-controlled trial, treatment with 1500 mg daily of resveratrol significantly decreased testosterone and dehydroepiandrosterone sulfate excess by ~23% in PCOS women over a period of 3 months [138].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Banaszewska, B., Wrotyńska-Barczyńska, J., Spaczynski, R. Z., Pawelczyk, L., & Duleba, A. J.
Affiliations
Poznan University of Medical Sciences (PL)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2016-11
Volume
101
Issue
11
Pages
4322-4328
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2532986090
Cited by
173
References
35
Citations by year
2026: 21 · 2025: 14 · 2024: 22 · 2023: 23 · 2022: 23 · 2021: 24 · 2020: 16 · 2019: 17 · 2018: 7 · 2017: 6
FWCI
13.29
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
Keywords
resveratrol, polycystic ovary syndrome, hyperandrogenism, serum total testosterone, dehydroepiandrosterone sulfate, insulin sensitivity, fasting insulin, insulin resistance, insulin-like growth factor I, ovarian androgen production, adrenal androgens, lipid profile, inflammation, endothelial function
MeSH terms
Resveratrol, Adult, Antioxidants, Double-Blind Method, Female, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Stilbenes, Testosterone, Outcome Assessment, Health Care, Dehydroepiandrosterone Sulfate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review